AINDEX
Markets

Myriad Genetics, Inc. (MYGN)

MYGNNASDAQ-GSBiotechnology: In Vitro & In Vivo Diagnostic Substances

$5.57

-0.0900 (-1.59%) today

At the close, Nov 16, 4:00 PM ET. After hours $5.57 –

-1.59% 1D
Market cap
$534.29m
P/E
–
EPS, last 4 quarters
$-0.6800
Dividend yield
–
Day range
$5.48 to $5.64
52-week range
$2.74 to $8.09
Average volume
–
Previous close
$5.66

Analysts

6 covering

Hold1 buy, 4 hold, 1 sell

Targets a year out average $5.69, +2.2% from here

$2.50now $5.57$8.00

Earnings

next estimate $-0.3300

Next report

Dec 2025

+118.2%

Mar 2026

0.0%

Jun 2026

-312.5%

Sep 2026

+16.0%

estimate reported, and the surprise

Financials

QuarterDec 2025Mar 2026Jun 2026Sep 2026
Revenue$209.80m$200.40m$190.70m$202.70m
Gross profit$146.80m$137.60m$127.00m$137.70m
Operating income-$5.70m-$30.70m-$38.90m-$39.90m
Net income-$7.90m-$34.10m-$43.20m-$43.90m

Last four quarters: revenue $803.60m, margin -16.1%, free cash flow -$33.90m

News

8 latest

The company

Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs.

Sector
Health Care
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
NASDAQ-GS
Region
North America
Website
myriad.com

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.